Responses to dupilumab (Dupixent) treatment were consistent across racial and ethnic groups in children with atopic ...

The following is a summary of “Dupilumab Improves Urticaria-Specific Quality of Life in Patients with Chronic Spontaneous ...

Dupilumab in atopic dermatitis treatment had the most favorable cardiometabolic safety profile when compared with methotrexate and cyclosporine.

Dupilumab improved exacerbations and lung function in patients with COPD and T2 inflammation, regardless of baseline BODE index score.

A study found that children with early-onset atopic dermatitis have a higher risk of developing uveitis and should be closely ...

A prospective registry study found a greater risk for infections associated with JAK inhibitors in adolescents and adults with moderate to severe atopic dermatitis compared with biologics.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

In this video, Raj Chovatiya, MD, PhD, discussed results of a study following patients with atopic dermatitis who were on lebrikizumab for 3 continuous years.

It’s not just in your stuffy head. Seasonal allergies are getting worse as pollen season gets longer and more intense.

In this video, Peter Lio, MD, discussed updates on topical agents, biologics and drugs in the pipeline in atopic dermatitis from presentations at the American Academy of Dermatology meeting.

18 months after saying "no" to regular NHS funding for Sanofi and Regeneron's Dupixent (dupilumab) for severe asthma in initial guidance, NICE has now backed the drug. The final appraisal ...

Sanofi is already a major player in the ASD market with its big-selling IL-4 and IL-13 inhibitor Dupixent (dupilumab), and the company has previously highlighted amlitelimab as one of a dozen ...